{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T18:46:45Z","timestamp":1781290005434,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Variants are globally emerging very quickly following pandemic prototypic SARS-CoV-2. To evaluate the cross-protection of prototypic SARS-CoV-2 vaccine against its variants, we vaccinated rhesus monkeys with three doses of prototypic SARS-CoV-2 inactivated vaccine, followed by challenging with emerging SARS-CoV-2 variants of concern (VOCs). These vaccinated animals produced neutralizing antibodies against Alpha, Beta, Delta, and Omicron variants, although there were certain declinations of geometric mean titer (GMT) as compared with prototypic SARS-CoV-2. Of note, in vivo this prototypic vaccine not only reduced the viral loads in nasal, throat and anal swabs, pulmonary tissues, but also improved the pathological changes in the lung infected by variants of Alpha, Beta, and Delta. In summary, the prototypic SARS-CoV-2 inactivated vaccine in this study protected against VOCs to certain extension, which is of great significance for prevention and control of COVID-19.<\/jats:p>","DOI":"10.1038\/s41392-022-00920-4","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T07:02:50Z","timestamp":1645772570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern"],"prefix":"10.1038","volume":"7","author":[{"given":"Tianhong","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-9735","authenticated-orcid":false,"given":"Shuaiyao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanlong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxiang","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexuan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-0247","authenticated-orcid":false,"given":"Xiaozhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"920_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola, M. et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J. Surg. 78, 185\u2013193 (2020).","journal-title":"Int J. Surg."},{"key":"920_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41591-021-01407-5","volume":"27","author":"O Milman","year":"2021","unstructured":"Milman, O. et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat. Med. 27, 1367\u20131369 (2021).","journal-title":"Nat. Med."},{"key":"920_CR3","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jama.2021.3199","volume":"325","author":"CB Creech","year":"2021","unstructured":"Creech, C. B., Walker, S. C. & Samuels, R. J. SARS-CoV-2 Vaccines. JAMA 325, 1318\u20131320 (2021).","journal-title":"JAMA"},{"key":"920_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516\u2013527 (2020).","journal-title":"Nature"},{"key":"920_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"920_CR6","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41591-021-01490-8","volume":"27","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat. Med. 27, 1693\u20131695 (2021).","journal-title":"Nat. Med."},{"key":"920_CR7","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Wheatley, A. K., Kent, S. J. & DeKosky, B. J. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 5, 1185\u20131191 (2020).","journal-title":"Nat. Microbiol."},{"key":"920_CR8","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1080\/21645515.2021.1969855","volume":"17","author":"A Hasan","year":"2021","unstructured":"Hasan, A., Al-Mulla, M. R., Abubaker, J. & Al-Mulla, F. Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination. Hum. Vaccin. Immunother. 17, 4121\u20134125 (2021).","journal-title":"Hum. Vaccin. Immunother."},{"key":"920_CR9","doi-asserted-by":"publisher","first-page":"108699","DOI":"10.1016\/j.celrep.2021.108699","volume":"34","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 34, 108699 (2021).","journal-title":"Cell Rep."},{"key":"920_CR10","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1056\/NEJMe2106315","volume":"384","author":"DB Cines","year":"2021","unstructured":"Cines, D. B. & Bussel, J. B. SARS-CoV-2 Vaccine\u2013Induced Immune Thrombotic Thrombocytopenia. N. Engl. J. Med. 384, 2254\u20132256 (2021).","journal-title":"N. Engl. J. Med"},{"key":"920_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1055\/a-1499-0119","volume":"121","author":"I Elalamy","year":"2021","unstructured":"Elalamy, I. et al. SARS-CoV-2 Vaccine and Thrombosis: an Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thromb. Haemost. 121, 982\u2013991 (2021).","journal-title":"Thromb. Haemost."},{"key":"920_CR12","doi-asserted-by":"publisher","first-page":"117607","DOI":"10.1016\/j.jns.2021.117607","volume":"428","author":"M Sharifian-Dorche","year":"2021","unstructured":"Sharifian-Dorche, M. et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J. Neurol. Sci. 428, 117607 (2021).","journal-title":"J. Neurol. Sci."},{"key":"920_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol"},{"key":"920_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet"},{"key":"920_CR15","doi-asserted-by":"publisher","unstructured":"VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01678-y (2022).","DOI":"10.1038\/s41591-021-01678-y"},{"key":"920_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMsr2105280","volume":"385","author":"PR Krause","year":"2021","unstructured":"Krause, P. R. et al. SARS-CoV-2 Variants and Vaccines. N. Engl. J. Med. 385, 179\u2013186 (2021).","journal-title":"N. Engl. J. Med"},{"key":"920_CR17","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1038\/s41423-021-00779-5","volume":"18","author":"P Arora","year":"2021","unstructured":"Arora, P. et al. The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. Cell Mol. Immunol. 18, 2673\u20132675 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"920_CR18","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","volume":"21","author":"SH Hodgson","year":"2021","unstructured":"Hodgson, S. H. et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect. Dis. 21, e26\u2013e35 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"920_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41392-020-00269-6","volume":"5","author":"S Lu","year":"2020","unstructured":"Lu, S. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Sig. Transduct. Target Ther. 5, 157 (2020).","journal-title":"Sig. Transduct. Target Ther."},{"key":"920_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41562-021-01122-8","volume":"5","author":"E Mathieu","year":"2021","unstructured":"Mathieu, E. et al. A global database of COVID-19 vaccinations. Nat. Hum. Behav. 5, 947\u2013953 (2021).","journal-title":"Nat. Hum. Behav."},{"key":"920_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMc2106757","volume":"385","author":"ASV Shah","year":"2021","unstructured":"Shah, A. S. V. et al. Effect of Vaccination on Transmission of SARS-CoV-2. N. Engl. J. Med. 385, 1718\u20131720 (2021).","journal-title":"N. Engl. J. Med"},{"key":"920_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(21)00468-2","volume":"397","author":"SSA Karim","year":"2021","unstructured":"Karim, S. S. A. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. Lancet (Lond., Engl.) 397, 1263\u20131264 (2021).","journal-title":"Lancet (Lond., Engl.)"},{"key":"920_CR23","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","volume":"384","author":"E Hacisuleyman","year":"2021","unstructured":"Hacisuleyman, E. et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N. Engl. J. Med. 384, 2212\u20132218 (2021).","journal-title":"N. Engl. J. Med."},{"key":"920_CR24","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N. Engl. J. Med. 385, 1474\u20131484 (2021).","journal-title":"N. Engl. J. Med"},{"key":"920_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.abg9175","volume":"372","author":"L Stamatatos","year":"2021","unstructured":"Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Sci. (N. Y., N. Y.) 372, 1413\u20131418 (2021).","journal-title":"Sci. (N. Y., N. Y.)"},{"key":"920_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"920_CR27","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","volume":"397","author":"KRW Emary","year":"2021","unstructured":"Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (Lond., Engl.) 397, 1351\u20131362 (2021).","journal-title":"Lancet (Lond., Engl.)"},{"key":"920_CR28","doi-asserted-by":"crossref","unstructured":"Bruxvoort, K. J. et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ 375 (2021).","DOI":"10.1136\/bmj-2021-068848"},{"key":"920_CR29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2021","unstructured":"Nemet, I. et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 386, 492\u2013494 (2021).","journal-title":"N. Engl. J. Med"},{"key":"920_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-18","volume":"10","author":"L Coudeville","year":"2010","unstructured":"Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010).","journal-title":"BMC Med. Res. Methodol."},{"key":"920_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476\u2013488.e411 (2021).","journal-title":"Cell"},{"key":"920_CR32","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1001\/jama.2021.4388","volume":"325","author":"VV Edara","year":"2021","unstructured":"Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA 325, 1896\u20131898 (2021).","journal-title":"JAMA"},{"key":"920_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"920_CR34","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"920_CR35","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe 3, e52\u2013e61 (2022).","journal-title":"Lancet Microbe"},{"key":"920_CR36","doi-asserted-by":"publisher","first-page":"e1008949","DOI":"10.1371\/journal.ppat.1008949","volume":"16","author":"H Zheng","year":"2020","unstructured":"Zheng, H. et al. Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: a nonhuman primate model of COVID-19 progression. PLoS Pathog. 16, e1008949 (2020).","journal-title":"PLoS Pathog."},{"key":"920_CR37","doi-asserted-by":"publisher","first-page":"e3949","DOI":"10.1093\/cid\/ciaa1703","volume":"73","author":"Y Che","year":"2020","unstructured":"Che, Y. et al. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clin. Infect. Dis. 73, e3949\u2013e3955 (2020).","journal-title":"Clin. Infect. Dis."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00920-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T19:02:11Z","timestamp":1669230131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-022-00920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1038\/s41392-022-00920-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}